LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025

Reuters11-18

LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025

LifeMD Inc. reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584671041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584671041","market":"us","top_or_hot":-1,"title":"LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LFMD\">LifeMD Inc.</a> reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LFMDP\">LifeMD Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LFMD\">LifeMD Inc.</a> reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LFMDP\">LifeMD Inc.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LFMD","symbol_name":"LifeMD Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbbkmtS:1","article_id":"2584671041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584671041","pubTimestamp":1763413898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"LifeMD Inc. reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LFMD":"LifeMD Inc.","BK4183":"个人用品","BK4167":"医疗保健技术"},"translate_title":"LifeMD报告2025年第三季度收入增长13%，调整后EBITDA增长20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFMD":0.9},"content_text":"LifeMD Reports 13% Revenue Growth and 20% Adjusted EBITDA Increase in Q3 2025\n    \n\nLifeMD Inc. reported third quarter 2025 total revenue of $60.2 million, an increase of 13% year-over-year. Telehealth revenue rose 18% to $47.3 million, with the number of active telehealth subscribers up 14% to approximately 310,000. Adjusted EBITDA increased 20% to $5.1 million, and telehealth adjusted EBITDA grew 30% to $2.9 million. The company paid off all outstanding debt during the quarter and, subsequent to quarter end, fully divested its majority stake in WorkSimpli. LifeMD is now focused as a pure-play telehealth and pharmacy platform, with continued diversification of its clinical offerings, including new launches in women's health, men's health, and psychiatry. For full-year 2025, LifeMD expects revenue between $192.0 million and $193.0 million, up approximately 24% from 2024, and adjusted EBITDA between $13.5 million and $14.5 million, an increase of about 254% versus 2024.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-023853), on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584671041","isCrawlerRequest":true}